All Posts Tagged With: "ACOR"
(ACOR) Company News for October 6, 2011 – Corporate Summary
• Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion • Reacting to news that Microsoft (NASDAQ:MSFT)...
6Oct2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates
Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during...
4Aug2011 | vitalstocks | 0 comments | Continued(ACOR) Company News for August 2, 2011 – Corporate Summary
• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion• Auxilium...
2Aug2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Inks Deal with Medtronic
Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for...
6Jul2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra
Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report...
16Jun2011 | vitalstocks | 0 comments | Continued(ACOR) Company News for May 23, 2011 – Corporate Summary
• Shares of Morgan Stanley (NYSE:MS) were guided lower after FrontPoint Partners LLC decided to close some of its hedge funds in which Morgan Stanley holds a minor stake by this month • After a regulatory filing disclosed that the chief scientist of Akamai Technologies...
23May2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermesto Buy Elan Unit for $960 Million
Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately...
9May2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations
Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating...
8May2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral
We recently downgraded Biogen Idec, Inc. (BIIB) to Neutral from our previous Outperform recommendation. Biogen is one of the world’s largest biotechnology companies. Its main areas of focus include neurology, oncology, hemophilia and immunology. Products such as Avonex (for...
3Oct2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
26Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
20Jul2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in Study
Biogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for their phase III study with daclizumab. The study– DECIDE, will evaluate the efficacy and safety of daclizumab in patients suffering from relapsing-remitting multiple sclerosis...
26May2010 | vitalstocks | 0 comments | Continued(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Apr2010 | vitalstocks | 0 comments | Continued(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics’ Multiple Sclerosis Drug Gets FDA Clearance
Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug...
25Jan2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen’s Tysabri is a Blockbuster!
Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for relapsing-remitting MS in the EU, achieved $1 billion in sales in 2009....
13Jan2010 | vitalstocks | 0 comments | Continued(FACT) Facet Biotech Rejects Biogen Idec Again
Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month,...
11Dec2009 | vitalstocks | 0 comments | Continued(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(ACOR) Acorda Therapeutics – Bull of the Day
Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside the U.S., Acorda has partnered...
8Nov2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Reports Higher Earnings
Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth...
20Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation
Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech...
20Oct2009 | vitalstocks | 0 comments | Continued(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer
In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet...
12Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech
After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash...
24Sep2009 | vitalstocks | 0 comments | Continued